AustenParker
樓主Alleyboi
:
Analysts project that Dexcom’s revenue will increase by approximately 15.1% annually, with earnings per share (EPS) expected to grow by 18.9% per annum. The company’s return on equity is forecasted to reach 37.9% over the next three years. Free cash flow is also expected to rise, with forecasts indicating an increase from $756.7 million in 2025 to $1.133 billion in 2026.
AustenParker
樓主AustenParker
樓主
:
Impact: Positive sentiment from analysts often encourages investor buying, further driving the share price upward. If Dexcom executes as expected—with sustained revenue growth, margin expansion, and successful product rollouts—its share price could appreciate significantly in 2025–2026. Short-term volatility may occur, but the medium- to long-term trajectory appears bullish based on current indicators
Alleyboi : why?
Alleyboi : Now a 100 share is $6600. Few months later you means it's worth $5000? Why?
AustenParker 樓主 Alleyboi : Analysts project that Dexcom’s revenue will increase by approximately 15.1% annually, with earnings per share (EPS) expected to grow by 18.9% per annum. The company’s return on equity is forecasted to reach 37.9% over the next three years.
Free cash flow is also expected to rise, with forecasts indicating an increase from $756.7 million in 2025 to $1.133 billion in 2026.
AustenParker 樓主 AustenParker 樓主 : Impact: Positive sentiment from analysts often encourages investor buying, further driving the share price upward.
If Dexcom executes as expected—with sustained revenue growth, margin expansion, and successful product rollouts—its share price could appreciate significantly in 2025–2026. Short-term volatility may occur, but the medium- to long-term trajectory appears bullish based on current indicators
Alleyboi : How do you calculate that $5000?
查看更多評論...